id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-0131-0001,FDA,FDA-2026-N-0131,FDA Rare Disease Innovation Hub Future Programming; Request for Comments,Notice,Request for Comments,2026-01-30,2026,1,2026-01-30,2027-01-01,2026-05-05 09:00:20,2026-01903,1,0,09000064b91893ee
FDA-2016-D-1280-0005,FDA,FDA-2016-D-1280,"Electronic Submission of Postmarketing Individual Case Safety Reports to the Food and Drug Administration Adverse Event Monitoring System Using International
Council of Harmonisation E2B(R3) Data Standards; Regional Data Elements and Implementation Schedule",Notice,Announcement,2026-04-06,2026,4,2026-04-06,2026-10-02,2026-04-07 09:00:25,2026-06660,1,0,09000064b9253dbc
FDA-2025-E-2426-0006,FDA,FDA-2025-E-2426,Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA,Notice,Determinations,2026-02-13,2026,2,2026-02-13,2026-08-13,2026-02-13 20:03:13,2026-02901,1,0,09000064b91aa6fb
FDA-2025-E-0152-0006,FDA,FDA-2025-E-0152,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:05:43,2026-02388,1,0,09000064b919467e
FDA-2025-E-0153-0006,FDA,FDA-2025-E-0153,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:06:34,2026-02388,1,0,09000064b919467f
FDA-2024-E-3539-0006,FDA,FDA-2024-E-3539,Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-14 13:19:52,2026-02387,1,0,09000064b9195b4d
FDA-2025-E-0154-0006,FDA,FDA-2025-E-0154,Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY,Notice,Determinations,2026-02-06,2026,2,2026-02-06,2026-08-06,2026-02-06 20:07:01,2026-02388,1,0,09000064b9195c17
FDA-2026-N-3273-0001,FDA,FDA-2026-N-3273,"Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments",Notice,Request for Comments,2026-04-15,2026,4,2026-04-15,2026-07-24,2026-04-15 17:05:22,2026-07248,1,0,09000064b9282224
FDA-2025-N-6895-0001,FDA,FDA-2025-N-6895,Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,Notice,Request for Comments,2026-04-16,2026,4,2026-04-16,2026-07-23,2026-05-17 09:00:23,2026-07361,1,0,09000064b92865ab
FDA-2026-P-0749-0001,FDA,FDA-2026-P-0749,Citizen Petition from Apotex Inc.,Other,Citizen Petition,2026-01-26,2026,1,2026-01-26,2026-07-23,2026-05-08 20:03:22,,1,0,09000064b9182c73
FDA-2026-D-1255-0002,FDA,FDA-2026-D-1255,Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry,Other,Guidance,2026-04-15,2026,4,2026-04-15,2026-07-15,2026-05-15 09:00:20,,1,0,09000064b9282a2a
FDA-2026-N-4126-0001,FDA,FDA-2026-N-4126,Azodicarbonamide (ADA); Request for Information,Notice,Requests for Information (RFI),2026-05-13,2026,5,2026-05-13,2026-07-14,2026-05-13 17:13:38,2026-09508,1,0,09000064b92d17fd
FDA-2026-N-3098-0001,FDA,FDA-2026-N-3098,Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting,Notice,60 Day Proposed Information Collection,2026-05-13,2026,5,2026-05-13,2026-07-14,2026-05-13 16:56:28,2026-09543,1,0,09000064b92d4966
FDA-2026-N-2526-0001,FDA,FDA-2026-N-2526,Butylated Hydroxytoluene (BHT); Request for Information,Notice,Requests for Information (RFI),2026-05-13,2026,5,2026-05-13,2026-07-14,2026-05-13 17:01:00,2026-09507,1,0,09000064b92d4931
FDA-2026-N-0005-0001,FDA,FDA-2026-N-0005,Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information,Notice,Requests for Information (RFI),2026-05-13,2026,5,2026-05-13,2026-07-14,2026-05-13 17:06:21,2026-09533,1,0,09000064b92d48f3
FDA-2023-N-0119-0020,FDA,FDA-2023-N-0119,"Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for
Comments",Notice,Request for Comments,2026-02-27,2026,2,2026-02-27,2026-07-11,2026-04-14 09:00:18,2026-03961,1,0,09000064b91e326c
FDA-2026-N-3070-0001,FDA,FDA-2026-N-3070,Agency Information Collection Activities; Proposed Collection; Comment Request; National Youth Tobacco Survey,Notice,60 Day Proposed Information Collection,2026-05-04,2026,5,2026-05-04,2026-07-07,2026-05-04 19:19:25,2026-08604,1,0,09000064b92c115c
FDA-2018-N-3240-0377,FDA,FDA-2018-N-3240,"List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act",Notice,Request for Comments,2026-05-01,2026,5,2026-05-01,2026-07-01,2026-05-17 09:00:24,2026-08552,1,0,09000064b92bb724
FDA-2026-N-3499-0001,FDA,FDA-2026-N-3499,Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments,Notice,Request for Comments,2026-05-01,2026,5,2026-05-01,2026-07-01,2026-05-02 09:00:17,2026-08521,1,0,09000064b92bb7fb
FDA-2026-N-3947-0001,FDA,FDA-2026-N-3947,Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments,Notice,Request for Comments,2026-05-01,2026,5,2026-05-01,2026-07-01,2026-05-09 09:00:22,2026-08524,1,0,09000064b92bb6d7
FDA-2026-N-4268-0001,FDA,FDA-2026-N-4268,Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments,Notice,Request for Comments,2026-05-01,2026,5,2026-05-01,2026-07-01,2026-05-09 09:00:22,2026-08499,1,0,09000064b92bb7b3
FDA-2026-N-3532-0001,FDA,FDA-2026-N-3532,Agency Information Collection Activities; Proposed Collection; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies,Notice,60 Day Proposed Information Collection,2026-04-30,2026,4,2026-04-30,2026-06-30,2026-05-02 09:00:17,2026-08371,1,0,09000064b92b7fb3
FDA-2026-N-2366-0001,FDA,FDA-2026-N-2366,Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments,Notice,Request for Comments,2026-03-23,2026,3,2026-03-23,2026-06-30,2026-05-01 09:00:14,2026-05573,1,0,09000064b922c21a
FDA-2026-N-1321-0001,FDA,FDA-2026-N-1321,"ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing",Notice,Withdrawal,2026-04-30,2026,4,2026-04-30,2026-06-30,2026-05-16 09:00:16,2026-08455,1,0,09000064b92b7e81
FDA-2025-D-6130-0002,FDA,FDA-2025-D-6130,Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry,Other,Guidance,2026-04-20,2026,4,2026-04-20,2026-06-23,2026-04-28 09:00:28,,1,0,09000064b92940ac
FDA-2025-D-7121-0002,FDA,FDA-2025-D-7121,"Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators; Draft Guidance for Industry and Food and Drug
Administration Staff",Other,Guidance,2026-04-20,2026,4,2026-04-20,2026-06-23,2026-05-06 09:00:15,,1,0,09000064b928d63f
FDA-2026-N-2917-0001,FDA,FDA-2026-N-2917,"Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed",Notice,60 Day Proposed Information Collection,2026-04-17,2026,4,2026-04-17,2026-06-17,2026-04-17 16:47:09,2026-07501,1,0,09000064b9289353
FDA-2026-N-3099-0001,FDA,FDA-2026-N-3099,Agency Information Collection Activities; Proposed Collection; Comment Request; Radioactive Drug Research Committees,Notice,60 Day Proposed Information Collection,2026-04-17,2026,4,2026-04-17,2026-06-17,2026-04-17 16:55:18,2026-07507,1,0,09000064b9289303
FDA-2025-E-0501-0006,FDA,FDA-2025-E-0501,Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT,Notice,Determinations,2026-04-16,2026,4,2026-04-16,2026-06-16,2026-04-16 17:49:56,2026-07422,1,0,09000064b928671f
FDA-2021-D-0613-0003,FDA,FDA-2021-D-0613,Stability Testing for Medicated Premixes (Revision 1); VICH GL8(R); Guidance for Industry; Draft Guidance; #91,Other,Guidance,2026-04-16,2026,4,2026-04-16,2026-06-16,2026-04-16 20:09:33,,1,0,09000064b9287b2e
FDA-2025-E-0502-0006,FDA,FDA-2025-E-0502,Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT,Notice,Determinations,2026-04-16,2026,4,2026-04-16,2026-06-16,2026-04-16 17:53:26,2026-07422,1,0,09000064b9286364
FDA-2026-N-3400-0001,FDA,FDA-2026-N-3400,Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs,Notice,60 Day Proposed Information Collection,2026-04-16,2026,4,2026-04-16,2026-06-16,2026-04-18 09:00:22,2026-07423,1,0,09000064b9286561
FDA-2026-N-3240-0001,FDA,FDA-2026-N-3240,Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs,Notice,60 Day Proposed Information Collection,2026-04-16,2026,4,2026-04-16,2026-06-16,2026-04-16 18:04:30,2026-07421,1,0,09000064b92866e7
FDA-2025-N-1600-0003,FDA,FDA-2025-N-1600,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3,Notice,30 Day Proposed Information Collection,2026-05-13,2026,5,2026-05-13,2026-06-13,2026-05-13 17:17:21,2026-09448,1,0,09000064b92d4828
FDA-2026-N-4492-0001,FDA,FDA-2026-N-4492,Drug Repurposing for Unmet Medical Needs; Request for Information,Notice,Requests for Information (RFI),2026-05-12,2026,5,2026-05-12,2026-06-12,2026-05-17 09:00:25,2026-09366,1,0,09000064b92d15f4
FDA-2026-N-2742-0001,FDA,FDA-2026-N-2742,Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification,Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-10 18:01:37,2026-06936,1,0,09000064b926825a
FDA-2026-N-2743-0001,FDA,FDA-2026-N-2743,"Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503",Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-20 09:00:32,2026-06935,1,0,09000064b926821b
FDA-2026-N-2915-0001,FDA,FDA-2026-N-2915,Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices,Notice,60 Day Proposed Information Collection,2026-04-10,2026,4,2026-04-10,2026-06-10,2026-04-10 17:47:50,2026-06906,1,0,09000064b9268328
FDA-2026-N-2431-0001,FDA,FDA-2026-N-2431,Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings,Notice,60 Day Proposed Information Collection,2026-04-07,2026,4,2026-04-07,2026-06-09,2026-05-12 09:00:14,2026-06719,1,0,09000064b9255485
FDA-2025-E-0863-0006,FDA,FDA-2025-E-0863,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:37:03,2026-06478,1,0,09000064b924cccb
FDA-2025-E-0845-0006,FDA,FDA-2025-E-0845,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:34:01,2026-06478,1,0,09000064b924dac3
FDA-2025-E-0866-0006,FDA,FDA-2025-E-0866,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:42:13,2026-06478,1,0,09000064b924ccce
FDA-2025-E-0372-0005,FDA,FDA-2025-E-0372,Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:52:42,2026-06476,1,0,09000064b924da88
FDA-2025-E-3074-0006,FDA,FDA-2025-E-3074,Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:57:30,2026-06480,1,0,09000064b924c470
FDA-2025-E-0871-0006,FDA,FDA-2025-E-0871,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:49:10,2026-06478,1,0,09000064b924c46e
FDA-2025-E-3073-0006,FDA,FDA-2025-E-3073,Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:55:54,2026-06480,1,0,09000064b924da86
FDA-2025-E-3626-0006,FDA,FDA-2025-E-3626,Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:59:57,2026-06479,1,0,09000064b924d98d
FDA-2025-E-0870-0006,FDA,FDA-2025-E-0870,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:48:07,2026-06478,1,0,09000064b924c46d
FDA-2026-N-2740-0001,FDA,FDA-2026-N-2740,Agency Information Collection Activities; Proposed Collection; Comment Request; Customer/Partner Customer Service Satisfaction Surveys,Notice,60 Day Proposed Information Collection,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:29:44,2026-06482,1,0,09000064b924dac4
FDA-2025-E-0868-0006,FDA,FDA-2025-E-0868,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:44:23,2026-06478,1,0,09000064b924c0e1
FDA-2025-E-0865-0006,FDA,FDA-2025-E-0865,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:39:45,2026-06478,1,0,09000064b924cccd
FDA-2025-E-1672-0007,FDA,FDA-2025-E-1672,Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:06:28,2026-06477,1,0,09000064b924d940
FDA-2014-E-2328-0006,FDA,FDA-2014-E-2328,Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:09:13,2026-06483,1,0,09000064b924d4f5
FDA-2025-E-0864-0006,FDA,FDA-2025-E-0864,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:38:27,2026-06478,1,0,09000064b924cccc
FDA-2025-E-0872-0006,FDA,FDA-2025-E-0872,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:50:02,2026-06478,1,0,09000064b924c46f
FDA-2025-E-0158-0006,FDA,FDA-2025-E-0158,Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 18:04:00,2026-06481,1,0,09000064b924d942
FDA-2025-E-0867-0006,FDA,FDA-2025-E-0867,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:43:31,2026-06478,1,0,09000064b924c0e0
FDA-2025-E-0869-0006,FDA,FDA-2025-E-0869,Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY,Notice,Determinations,2026-04-03,2026,4,2026-04-03,2026-06-03,2026-04-03 17:45:32,2026-06478,1,0,09000064b924ba07
FDA-2026-N-0499-0002,FDA,FDA-2026-N-0499,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice,Notice,30 Day Proposed Information Collection,2026-04-30,2026,4,2026-04-30,2026-06-02,2026-04-30 17:46:42,2026-08417,1,0,09000064b92b80f2
FDA-2026-C-3071-0001,FDA,FDA-2026-C-3071,"Filing of Color Additive Petition: International Association of Color Manufacturers; Request to Amend the Color Additive Regulations to Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride",Proposed Rule,Petition,2026-04-01,2026,4,2026-04-01,2026-06-02,2026-04-01 17:16:12,2026-06295,1,0,09000064b9249960
FDA-2026-N-0809-0001,FDA,FDA-2026-N-0809,Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments,Notice,Request for Comments,2026-03-03,2026,3,2026-03-03,2026-06-02,2026-05-07 09:00:19,2026-04196,1,0,09000064b91ed501
FDA-2026-N-2476-0001,FDA,FDA-2026-N-2476,"Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products;
Request for Information and Comments",Notice,Request for Comments,2026-03-31,2026,3,2026-03-31,2026-06-02,2026-05-17 09:00:21,2026-06184,1,0,09000064b92439d6
FDA-2026-N-4390-0001,FDA,FDA-2026-N-4390,AI-Enabled Optimization of Early- Phase Clinical Trials Pilot Program; Request for Information,Notice,Requests for Information (RFI),2026-04-29,2026,4,2026-04-29,2026-05-30,2026-05-17 09:00:24,2026-08281,1,0,09000064b92b54c8
FDA-2026-N-2590-0001,FDA,FDA-2026-N-2590,Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests,Proposed Rule,Request for Comment,2026-03-30,2026,3,2026-03-30,2026-05-30,2026-05-13 09:00:24,2026-06064,1,0,09000064b92437b6
FDA-2026-N-3962-0001,FDA,FDA-2026-N-3962,"Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—
United States (U.S.) 2026–2027 Formula for COVID–19 Vaccine Composition",Notice,Request for Comments,2026-04-27,2026,4,2026-04-27,2026-05-28,2026-05-17 09:00:24,2026-08122,1,0,09000064b92ad21d
FDA-2026-N-2642-0001,FDA,FDA-2026-N-2642,Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments,Notice,Request for Comments,2026-04-23,2026,4,2026-04-23,2026-05-27,2026-05-16 09:00:16,2026-07910,1,0,09000064b92a4e3b
FDA-2024-E-5140-0006,FDA,FDA-2024-E-5140,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:48,2025-20667,1,0,09000064b908e3f0
FDA-2024-E-5139-0006,FDA,FDA-2024-E-5139,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:48,2025-20667,1,0,09000064b908e3ef
FDA-2024-E-5141-0006,FDA,FDA-2024-E-5141,Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM,Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2026-01-24 13:16:50,2025-20667,1,0,09000064b9092f99
FDA-2024-E-5681-0006,FDA,FDA-2024-E-5681,"Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION
SYSTEM",Notice,Determinations,2025-11-24,2025,11,2025-11-24,2026-05-27,2025-11-24 19:32:14,2025-20668,1,0,09000064b9093521
FDA-2026-N-2365-0001,FDA,FDA-2026-N-2365,Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees,Notice,60 Day Proposed Information Collection,2026-03-23,2026,3,2026-03-23,2026-05-23,2026-03-23 17:37:47,2026-05620,1,0,09000064b922c25e
FDA-2026-N-2364-0001,FDA,FDA-2026-N-2364,"Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug
Administration Advisory Committees",Notice,60 Day Proposed Information Collection,2026-03-23,2026,3,2026-03-23,2026-05-23,2026-03-25 09:00:29,2026-05623,1,0,09000064b922c187
FDA-2025-D-2837-0002,FDA,FDA-2025-D-2837,Questions and Answers About Requirements for Additional Traceability Records for Certain Foods: Guidance for Industry - Draft Guidance,Other,Guidance,2026-02-20,2026,2,2026-02-20,2026-05-22,2026-02-20 20:47:16,,1,0,09000064b91c9d9a
FDA-2026-N-1304-0001,FDA,FDA-2026-N-1304,Agenda for the U.S. Food and Drug Administration (FDA) Virtual Public Meeting Food Allergen Thresholds and Their Potential Applications 2-18-2026,Other,Agenda,2026-02-18,2026,2,2026-02-18,2026-05-20,2026-05-17 09:00:21,,1,0,09000064b91b5eeb
FDA-2025-N-5995-0001,FDA,FDA-2025-N-5995,Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2026-03-18,2026,3,2026-03-18,2026-05-19,2026-03-21 09:00:16,2026-05322,1,0,09000064b92215cb
FDA-2025-N-5996-0001,FDA,FDA-2025-N-5996,Medical Devices; Radiology Devices; Classification of Blood Irradiators,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2026-03-18,2026,3,2026-03-18,2026-05-19,2026-05-07 09:00:21,2026-05320,1,0,09000064b92216a5
FDA-2026-N-1849-0001,FDA,FDA-2026-N-1849,Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notifications Submission,Notice,60 Day Proposed Information Collection,2026-03-19,2026,3,2026-03-19,2026-05-19,2026-03-19 17:24:48,2026-05329,1,0,09000064b9224334
FDA-2026-N-2279-0001,FDA,FDA-2026-N-2279,Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR–20); Request for Comments,Notice,Request for Comments,2026-03-18,2026,3,2026-03-18,2026-05-19,2026-05-12 09:00:12,2026-05280,1,0,09000064b922165c
FDA-2025-D-6131-0002,FDA,FDA-2025-D-6131,General Considerations for the Use of New Approach Methodologies in Drug Development; Guidance for Industry - Draft Guidance,Other,Guidance,2026-03-19,2026,3,2026-03-19,2026-05-19,2026-05-16 09:00:11,,1,0,09000064b9223609